Literature DB >> 21630409

Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Aβ40 amyloid formation and cytotoxicity.

Erika Andreetto1, Li-Mei Yan, Andrea Caporale, Aphrodite Kapurniotu.   

Abstract

Alzheimer's disease (AD) and type 2 diabetes (T2D) are linked to the self-association of β-amyloid peptide (Aβ) and islet amyloid polypeptide (IAPP), respectively. We have shown that IAPP-GI, a soluble IAPP analogue and mimic of nonamyloidogenic and nontoxic IAPP, binds Aβ with high affinity and blocks its cytotoxic self-assembly and fibrillogenesis. We have also shown that IAPP and Aβ interact with each other into nonfibrillar and nontoxic heterocomplexes that suppress cytotoxic self-association by both polypeptides. The Aβ-IAPP interaction might thus be a molecular link between AD and T2D. We studied the role of individual IAPP-GI and IAPP regions in their inhibitory function on Aβ40 self-association and cytotoxicity. We found that the presence of the two hot-spot regions of the Aβ-IAPP interaction interface in IAPP(8-28) is not sufficient for inhibitory function and that, in addition to IAPP(8-28), the presence of the N-terminal region IAPP(1-7) is absolutely required. By contrast, the C-terminal region, IAPP(30-37), is not required although its presence together with IAPP(1-7) in IAPP-GI results in a marked enhancement of the inhibitory effect as compared to IAPP(1-28)-GI. We suggest that the inhibitory effect of IAPP-GI and IAPP on Aβ40 fibrillogenesis and cell toxicity is mediated primarily by interactions involving the hot regions of the Aβ-IAPP interaction interface and the N terminus of IAPP while a concerted and likely structure-stabilizing action of the N- and C-terminal IAPP regions potentiates this effect. These results identify important molecular determinants of the amyloid suppressing function of the Aβ40-IAPP interaction and could contribute to the design of novel inhibitors of Aβ40 aggregation and cell degeneration.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630409     DOI: 10.1002/cbic.201100192

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  11 in total

Review 1.  Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.

Authors:  Wei Qiao Qiu
Journal:  Neuroscience       Date:  2017-05-19       Impact factor: 3.590

2.  Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways.

Authors:  Wen Fu; Araya Ruangkittisakul; David MacTavish; Jenny Y Shi; Klaus Ballanyi; Jack H Jhamandas
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

3.  Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons.

Authors:  Qini Gan; Hongbo Yao; Hana Na; Heather Ballance; Qiushan Tao; Lorene Leung; Hua Tian; Haihao Zhu; Benjamin Wolozin; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  Simulations of cross-amyloid aggregation of amyloid-β and islet amyloid polypeptide fragments.

Authors:  Grant E Kawecki; Kelsie M King; Nicholas A Cramer; David R Bevan; Anne M Brown
Journal:  Biophys J       Date:  2022-05-10       Impact factor: 3.699

5.  S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation.

Authors:  Hugo M Botelho; Sónia S Leal; Isabel Cardoso; Kiran Yanamandra; Ludmilla A Morozova-Roche; Günter Fritz; Cláudio M Gomes
Journal:  J Biol Chem       Date:  2012-10-17       Impact factor: 5.157

6.  Positive association between plasma amylin and cognition in a homebound elderly population.

Authors:  Wei Qiao Qiu; Rhoda Au; Haihao Zhu; Max Wallack; Elizabeth Liebson; Huajie Li; James Rosenzweig; Mkaya Mwamburi; Robert A Stern
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.

Authors:  H Zhu; X Wang; M Wallack; H Li; I Carreras; A Dedeoglu; J-Y Hur; H Zheng; H Li; R Fine; M Mwamburi; X Sun; N Kowall; R A Stern; W Q Qiu
Journal:  Mol Psychiatry       Date:  2014-03-11       Impact factor: 15.992

8.  Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Authors:  Wei Qiao Qiu; Haihao Zhu
Journal:  Front Aging Neurosci       Date:  2014-07-29       Impact factor: 5.750

Review 9.  Peptide-Protein Interactions: From Drug Design to Supramolecular Biomaterials.

Authors:  Andrea Caporale; Simone Adorinni; Doriano Lamba; Michele Saviano
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

Review 10.  On the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP Peptides.

Authors:  Marianna Flora Tomasello; Alessandro Sinopoli; Giuseppe Pappalardo
Journal:  J Diabetes Res       Date:  2015-10-25       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.